Cardioxyl Pharmaceuticals Initiates First Clinical Trial Of CXL-1427 CHAPEL HILL, N.C., Feb. 25, 2014 /PRNewswire/ -- Cardioxyl Pharmaceuticals, Inc. announced today that the first cohort of patients has been dosed in a Phase I clinical trial of CXL-1427, a novel nitroxyl (HNO) prodrug optimized for clinical development as a potential treatment for acute decompensated heart failure (ADHF). The primary objective of the Phase 1 clinical trial is to evaluate the ...
Feb. 25, 2014 - PR Newswire via Yahoo! Finance